Total medical devices industry cross border deals worth $3.33bn were announced globally for January 2021, with the $880.85m asset transaction with Novasep Holding being the sector’s biggest investment, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 33.1% over the previous month of $4.98bn and a rise of 25.2% when compared with the last 12-month average of $2.66bn.

In terms of number of cross border deals, the sector saw a drop of 7.69% with 36 deals in January 2021 when compared to the last 12-month average of 39 deals.

In value terms, Europe led the activity with cross border deals worth $2.06bn in January 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Medical Devices industry cross border deals in January 2021: Top deals

The top five cross border deals accounted for 81.4% of the overall value during January 2021.

The combined value of the top five cross border deals stood at $2.71bn, against the overall value of $3.33bn recorded for the month.

The top five medical devices industry cross border deals of January 2021 tracked by GlobalData were:

1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding

2) The $635m acquisition of Capsule Technologies by Koninklijke Philips

3) PerkinElmer’s $591m acquisition of Oxford Immunotec

4) The $409.7m acquisition deal of Handicare Group by Savaria

5) Atinum Investment, HBM Healthcare Investments, Invus Public Equities, Mirae Asset Capital and Public Sector Pension Investment Board’s venture financing deal with Valo Health for $190m.